Pieris Pharmaceuticals Stock Analysis

PIRS Stock  USD 7.69  0.29  3.92%   
Pieris Pharmaceuticals is overvalued with Real Value of 7.0 and Target Price of 7.0. The main objective of Pieris Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Pieris Pharmaceuticals is worth, separate from its market price. There are two main types of Pieris Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Pieris Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Pieris Pharmaceuticals is usually not traded on Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Pieris Stock trading window is adjusted to America/New York timezone.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.

Pieris Stock Analysis Notes

About 37.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.64. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pieris Pharmaceuticals recorded a loss per share of 11.4. The entity had not issued any dividends in recent years. The firm had 1:80 split on the 23rd of April 2024. Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts. Pieris Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people. To find out more about Pieris Pharmaceuticals contact Stephen JD at 857 246 8998 or learn more at https://www.pieris.com.

Pieris Pharmaceuticals Investment Alerts

Pieris Pharmaceuticals generated a negative expected return over the last 90 days
Pieris Pharmaceuticals has high historical volatility and very poor performance
Pieris Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 42.81 M. Net Loss for the year was (24.54 M) with loss before overhead, payroll, taxes, and interest of (27.08 M).
Pieris Pharmaceuticals currently holds about 80.94 M in cash with (53.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.09.
Pieris Pharmaceuticals has a poor financial position based on the latest SEC disclosures
Latest headline from news.google.com: Pivots Trading Plans and Risk Controls - Stock Traders Daily

Pieris Pharmaceuticals Upcoming and Recent Events

3rd of April 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Pieris Largest EPS Surprises

Earnings surprises can significantly impact Pieris Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2018-08-09
2018-06-30-0.01-0.00380.006262 
2022-11-02
2022-09-30-0.16-0.130.0318 
2022-08-04
2022-06-30-0.11-0.14-0.0327 
View All Earnings Estimates

Pieris Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Pieris Pharmaceuticals' ESG score is a quantitative measure that evaluates Pieris Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Pieris Pharmaceuticals' operations that may have significant financial implications and affect Pieris Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.

Pieris Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Goldman Sachs Group Inc2023-12-31
45.3 K
Xtx Topco Ltd2023-12-31
39.7 K
Two Sigma Advisers, Llc2023-12-31
34.6 K
Nj State Employees Deferred Compnstin Pl2023-12-31
30 K
Raymond James & Associates2024-03-31
30 K
Commerce Bank Na/mo2023-12-31
20 K
Kestra Advisory Services, Llc2023-12-31
17.5 K
Two Sigma Securities, Llc2023-12-31
15.4 K
Hudson Valley Investment Advisors, Llc2024-03-31
14 K
Renaissance Technologies Corp2023-12-31
1.1 M
Blackrock Inc2023-12-31
M
Note, although Pieris Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Pieris Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.42 M.

Pieris Profitablity

The company has Profit Margin (PM) of (0.4) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (100.06) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $100.06.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.63)(0.67)
Return On Capital Employed(0.59)(0.62)
Return On Assets(0.63)(0.67)
Return On Equity(0.92)(0.96)

Management Efficiency

Pieris Pharmaceuticals has return on total asset (ROA) of (0.063) % which means that it has lost $0.063 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8686) %, meaning that it created substantial loss on money invested by shareholders. Pieris Pharmaceuticals' management efficiency ratios could be used to measure how well Pieris Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.67 in 2024. Return On Capital Employed is likely to drop to -0.62 in 2024. At this time, Pieris Pharmaceuticals' Total Current Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 1.7 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 31.6 M in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 23.77  35.22 
Tangible Book Value Per Share 23.77  35.22 
Enterprise Value Over EBITDA 0.07  0.08 
Price Book Value Ratio 0.61  0.58 
Enterprise Value Multiple 0.07  0.08 
Price Fair Value 0.61  0.58 
Enterprise Value126.1 M67.6 M
The analysis of Pieris Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Pieris Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Pieris Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Operating Margin
(100.06)
Profit Margin
(0.40)
Beta
0.682
Return On Assets
(0.06)
Return On Equity
(0.87)

Technical Drivers

As of the 18th of July 2024, Pieris Pharmaceuticals holds the Coefficient Of Variation of (411.91), risk adjusted performance of (0.14), and Variance of 12.81. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pieris Pharmaceuticals, as well as the relationship between them. Please check Pieris Pharmaceuticals coefficient of variation and value at risk to decide if Pieris Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 7.69 per share. Given that Pieris Pharmaceuticals has information ratio of (0.28), we recommend you to check out Pieris Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.

Pieris Pharmaceuticals Price Movement Analysis

Execute Study
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Pieris Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Pieris Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Pieris Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pieris Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pieris Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pieris Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Pieris Pharmaceuticals Outstanding Bonds

Pieris Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pieris Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pieris bonds can be classified according to their maturity, which is the date when Pieris Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Pieris Pharmaceuticals Predictive Daily Indicators

Pieris Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pieris Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Pieris Pharmaceuticals Corporate Filings

8K
3rd of July 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
17th of May 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
10Q
15th of May 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
8K
9th of May 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
10K
29th of April 2024
An amendment to a previously filed Form 10-K
ViewVerify
8K
18th of April 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
10K
29th of March 2024
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
ViewVerify
8K
27th of March 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Pieris Pharmaceuticals Forecast Models

Pieris Pharmaceuticals' time-series forecasting models are one of many Pieris Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pieris Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Pieris Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Pieris Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Pieris shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Pieris Pharmaceuticals. By using and applying Pieris Stock analysis, traders can create a robust methodology for identifying Pieris entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.57)(0.60)
Operating Profit Margin(0.37)(0.39)
Net Loss(0.57)(0.60)
Gross Profit Margin 0.96  1.01 

Current Pieris Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Pieris analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Pieris analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
7.0Hold1Odds
Pieris Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Pieris analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Pieris stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Pieris Pharmaceuticals, talking to its executives and customers, or listening to Pieris conference calls.
Pieris Analyst Advice Details

Pieris Stock Analysis Indicators

Pieris Pharmaceuticals stock analysis indicators help investors evaluate how Pieris Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Pieris Pharmaceuticals shares will generate the highest return on investment. By understating and applying Pieris Pharmaceuticals stock analysis, traders can identify Pieris Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow38.6 M
Common Stock Shares Outstanding1.1 M
Total Stockholder Equity26.8 M
Cash And Short Term Investments26.4 M
Cash17.4 M
Accounts Payable3.4 M
Net Debt-17.4 M
50 Day M A9.7279
Total Current Liabilities11.9 M
Other Operating Expenses58.7 M
Stock Based Compensation3.3 M

Additional Tools for Pieris Stock Analysis

When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.